Stock Events

Stock Events

Helus Pharma 

$13.01
480
-$0.01-0.08% 08:02 Today

Statistics

Day High
13.24
Day Low
11.94
52W High
13.24
52W Low
3.76
Volume
1,862,894
Avg. Volume
1,514,274
Mkt Cap
951.24M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q4 2025
Q2 2026
Next
-2
-1.34
-0.68
-0.02
Expected EPS
-0.6129703542926399
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-148MNet Income

Analyst Ratings

47.50Average Price Target
The highest estimate is 70.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HELP. It's not an investment recommendation.
iShares Core Equity Portfolio
22
XEQT.TO
Vanguard S&P 500 Index
19
VFV.TO
NVIDIA
18
NVDA
Bitcoin
17
BTC.CRYPTO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Compass Pathways
CMPS
Mkt Cap1.85B
Compass Pathways operates in the psychedelic medicine space, focusing on psilocybin therapy for depression, directly competing with Cybin's psychedelic-based treatments.
AtaiBeckley
ATAI
Mkt Cap2.74B
ATAI Life Sciences is a biotech company with a focus on psychedelic and non-psychedelic compounds for mental health, making it a direct competitor to Cybin.
GH Research
GHRS
Mkt Cap1.94B
GH Research is involved in the development of therapeutics based on DMT for depression, competing in the same psychedelic treatment space as Cybin.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness focuses on psychedelic production and therapy, including psilocybin and MDMA, competing in the mental health treatment market alongside Cybin.
Revive Therapeutics
RVVTF
Mkt Cap9.15M
Revive Therapeutics is exploring the use of psychedelics for the treatment of various conditions, including mental health disorders, making it a competitor to Cybin.
PSYC
PSYC
Mkt Cap135,518
Psyched Wellness is focused on the development of psychedelic products, including Amanita Muscaria, competing in the broader psychedelic wellness market.
TripAdvisor
TRIP
Mkt Cap1.17B
Red Light Holland is involved in the production, growth, and sale of a premium brand of magic truffles, competing in the psychedelic substances market relevant to Cybin's interests.

About

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Show more...
CEO
Michael Halstead
Employees
50
Country
Canada
ISIN
CA23256X4075
WKN
000A40NJY

Listings

STU
DE
R7E.STU
MU
DE
R7E1.MU
STU
DE
R7E1.STU
MU
DE
R7E.MU

0 Comments

Share your thoughts

FAQ

What is Helus Pharma stock price today?▼
The current price of HELP is $13.01 USD — it has decreased by -0.08% in the past 24 hours. Watch Helus Pharma stock price performance more closely on the chart.
What is Helus Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Helus Pharma stocks are traded under the ticker HELP.
What is Helus Pharma market cap?▼
Today Helus Pharma has the market capitalization of 951.24M
When is the next Helus Pharma earnings date?▼
Helus Pharma is going to release the next earnings report on November 16, 2026.
What were Helus Pharma earnings last quarter?▼
HELP earnings for the last quarter are -0.89 USD per share, whereas the estimation was -0.84 USD resulting in a -6.35% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Helus Pharma revenue for the last year?▼
Helus Pharma revenue for the last year amounts to 0 USD.
What is Helus Pharma net income for the last year?▼
HELP net income for the last year is -148M USD.
How many employees does Helus Pharma have?▼
As of August 25, 2026, the company has 50 employees.
In which sector is Helus Pharma located?▼
Helus Pharma operates in the Health & Wellness sector.
When did Helus Pharma complete a stock split?▼
Helus Pharma has not had any recent stock splits.
Where is Helus Pharma headquartered?▼
Helus Pharma is headquartered in Toronto, Canada.